Jatinder Kaur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/749126/publications.pdf

Version: 2024-02-01

39	11,508	430874	302126
papers	citations	18 h-index	39 g-index

42	42	42	28714
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	In situ click chemistry generation of cyclooxygenase-2 inhibitors. Nature Communications, 2017, 8, 1.	12.8	10,736
2	Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus. Journal of Medicinal Chemistry, 2020, 63, 9540-9562.	6.4	57
3	Critical Review of Bioadsorption on Modified Cellulose and Removal of Divalent Heavy Metals (Cd, Pb,) Tj ETQq1 1 0.784314 rgBT /Ov	3.7	54
4	Structureâ€“Activity Relationship Studies of Acetazolamide-Based Carbonic Anhydrase Inhibitors with Activity against Neisseria gonorrhoeae. ACS Infectious Diseases, 2021, 7, 1969-1984.	3.8	48
5	N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: Synthesis and biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2154-2159.	2.2	41
6	ATP selective acridone based fluorescent probes for monitoring of metabolic events. Chemical Communications, 2011, 47, 4472.	4.1	38
7	Hybrid fluorescent conjugates of COX-2 inhibitors: Search for a COX-2 isozyme imaging cancer biomarker. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 163-168.	2.2	37
8	Fluorophoreâ€Labeled Cyclooxygenaseâ€2 Inhibitors for the Imaging of Cyclooxygenaseâ€2 Overexpression in Cancer: Synthesis and Biological Studies. ChemMedChem, 2014, 9, 109-116.	3.2	36
9	Search for MDR modulators: Design, syntheses and evaluations of N-substituted acridones for interactions with p-glycoprotein and Mg2+. Bioorganic and Medicinal Chemistry, 2009, 17, 2423-2427.	3.0	35
10	Synthesis and Biological Investigations of Nitric Oxide Releasing Nateglinide and Meglitinide Type II Antidiabetic Prodrugs: In-Vivo Antihyperglycemic Activities and Blood Pressure Lowering Studies. Journal of Medicinal Chemistry, 2012, 55, 7883-7891.	6.4	33
11	Design, synthesis and evaluations of acridone derivatives using Candida albicansâ€"Search for MDR modulators led to the identification of an anti-candidiasis agent. Bioorganic and Medicinal Chemistry, 2009, 17, 3973-3979.	3.0	30
12	Synthesis of three 18F-labelled cyclooxygenase-2 (COX-2) inhibitors based on a pyrimidine scaffold. Organic and Biomolecular Chemistry, 2013, 11, 8052.	2.8	28
13	Design, Synthesis, and Evaluation of an ¹⁸Fâ€Labeled Radiotracer Based on Celecoxibâ€“NBD for Positron Emission Tomography (PET) Imaging of Cyclooxygenaseâ€2 (COXâ€2). ChemMedChem, 2015, 10, 1635-1640.	3.2	27
14	Acridone based Cu2+â€“Fâ^'/Fâ^'â€“Cu2+ responsive ON/OFF key pad. Sensors and Actuators B: Chemical, 2010, 150, 50-56.	7.8	26
15	Acridine derivatives: a patent review (2009 â€“ 2010). Expert Opinion on Therapeutic Patents, 2011, 21, 437-454.	5.0	24
16	Rofecoxib Analogues Possessing a Nitric Oxide Donor Sulfohydroxamic Acid (SO₂NHOH) Cyclooxygenaseâ€2 Pharmacophore: Synthesis, Molecular Modeling, and Biological Evaluation as Antiâ€inflammatory Agents. ChemMedChem, 2012, 7, 62-67.	3.2	24
17	Optimization of a 1,3,4-oxadiazole series for inhibition of Ca2+/calmodulin-stimulated activity of adenylyl cyclases 1 and 8 for the treatment of chronic pain. European Journal of Medicinal Chemistry, 2019, 162, 568-585.	5.5	22
18	Aspirin Analogues as Dual Cyclooxygenaseâ€2/5â€Lipoxygenase Inhibitors: Synthesis, Nitric Oxide Release, Molecular Modeling, and Biological Evaluation as Antiâ€inflammatory Agents. ChemMedChem, 2012, 7, 144-150.	3.2	20

#	Article	IF	Citations
19	O²-Sulfonylethyl Protected Isopropylamine Diazen-1-ium-1,2-diolates as Nitroxyl (HNO) Donors: Synthesis, Î²-Elimination Fragmentation, HNO Release, Positive Inotropic Properties, and Blood Pressure Lowering Studies. Journal of Medicinal Chemistry, 2012, 55, 10262-10271.	6.4	19
20	Synthesis of highly functionalized barbituric acids and study of their interactions with p-glycoprotein and Mg2+ â€“ Potential candidates for multi drug resistance modulation. European Journal of Medicinal Chemistry, 2010, 45, 1256-1262.	5.5	18
21	Cardiovascular Properties of a Nitric Oxide Releasing Rofecoxib Analogue: Beneficial Antiâ€hypertensive Activity and Enhanced Recovery in an Ischemic Reperfusion Injury Model. ChemMedChem, 2012, 7, 1365-1368.	3.2	17
22	Synthesis, bioassay studies, and molecular docking of novel 5-substituted 1H tetrazoles as cyclooxygenase-2 (COX-2) inhibitors. Medicinal Chemistry Research, 2015, 24, 78-85.	2.4	17
23	Glutathione S-Transferase Ï€-Activatable O²-(Sulfonylethyl Derived) Diazeniumdiolates Potently Suppress Melanoma in Vitro and in Vivo. Journal of Medicinal Chemistry, 2018, 61, 1833-1844.	6.4	17
24	Fluorescent Hexose Conjugates Establish Stringent Stereochemical Requirement by GLUT5 for Recognition and Transport of Monosaccharides. ACS Chemical Biology, 2017, 12, 1087-1094.	3.4	16
25	Targeting efflux pumpsâ€"In vitro investigations with acridone derivatives and identification of a lead molecule for MDR modulation. Bioorganic and Medicinal Chemistry, 2010, 18, 4212-4223.	3.0	15
26	1,4-Diaryl-substituted triazoles as cyclooxygenase-2 inhibitors: Synthesis, biological evaluation and molecular modeling studies. Bioorganic and Medicinal Chemistry, 2013, 21, 4288-4295.	3.0	14
27	Isomeric acetoxy analogs of celecoxib and their evaluation as cyclooxygenase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6074-6080.	2.2	11
28	Pyrimidine-based fluorescent COX-2 inhibitors: synthesis and biological evaluation. Organic and Biomolecular Chemistry, 2016, 14, 7250-7257.	2.8	11
29	Development of Fluorescence Imaging Probes for Labeling COX-1 in Live Ovarian Cancer Cells. ACS Medicinal Chemistry Letters, 2021, 12, 798-804.	2.8	5
30	Novel therapeutic heterocycles as selective cyclooxygenase-2 inhibitors and anti-cancer agents: Synthesis, in vitro bioassay screenings, and molecular docking studies. Journal of Molecular Structure, 2022, 1263, 133141.	3.6	5
31	Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks?. Future Medicinal Chemistry, 2013, 5, 381-383.	2.3	4
32	Cu(II) complexes of hydrazonesâ€"NSAID conjugates: synthesis, characterization and anticancer activity. Journal of Coordination Chemistry, 2020, 73, 3186-3202.	2.2	4
33	In Cellulo Generation of Fluorescent Probes for Liveâ€Cell Imaging of Cylooxygenaseâ€2. Chemistry - A European Journal, 2021, 27, 3326-3337.	3.3	4
34	Synthesis and Biological Evaluation of 1,3,5â€Trisubstituted 2â€Pyrazolines as Novel Cyclooxygenaseâ€2 Inhibitors with Antiproliferative Activity. Chemistry and Biodiversity, 2021, 18, e2000832.	2.1	4
35	Do nitric oxide-releasing drugs offer a potentially new paradigm for the management of cardiovascular risks in diabetes?. Expert Review of Cardiovascular Therapy, 2014, 12, 533-536.	1.5	3
36	Optimization of a Pyrimidinone Series for Selective Inhibition of Ca²⁺/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain. Journal of Medicinal Chemistry, 2022, 65, 4667-4686.	6.4	3

#	Article	IF	Citations
37	A diazen-1-ium-1,2-diolate analog of 7-azabenzobicyclo[2.2.1]heptane: Synthesis, nitric oxide and nitroxyl release, in vitro hemodynamic, and anti-hypertensive studies. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2769-2774.	2.2	2
38	Ruthenium(II) complexes of aroylhydrazones: structural, electrochemical and electrostatic interactions with DNA. Journal of Coordination Chemistry, 2017, 70, 1667-1682.	2.2	2
39	Fluorine-18 Labelled Radioligands for PET Imaging of Cyclooxygenase-2. Molecules, 2022, 27, 3722.	3.8	1